NANOG and ovarian carcinoma: To test the relevance of the Src pathway in the acquisition of a CSC phenotype, we generated ovarian cancer tumorspheres in the presence of PP2, a Src inhibitor which suppressed the expression of two master regulators of the CSC phenotype, CD133 and NANOG.